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Sir,
Because Helicobacter pylori (HP) is widely accepted as a risk
factor for gastric carcinoma (Blaser, 1999; Scheiman and Cutler,
1999), mass eradication has been proposed to prevent this
common neoplasm (Scheiman and Cutler, 1999; Danesh, 1999).
The postulated causal relationship, however, may be distorted by
detection bias in which a ‘silent’ cancer is coincidentally found
when dyspeptic symptoms lead to an earlier diagnostic study.
Evidence of this effect is an increased stage ratio of invasive/non-
invasive gastric cancer in patients without HP.
During a search of factors associated with presentation stage in
373 patients diagnosed with gastric cancer in the years between
December of 1987–1998, we found a higher frequency of HP in
biopsies of patients with non-invasive TNM stages I and II (14/49,
28.6%) than in those with invasive TNM stages III–IV (38/324,
11.7%) (P = 0.0034). The invasive to non-invasive stage ratio was
6.6:1. This finding was independent of other factors also showing
a significant association such as socio-economic status and the
interval between the onset of symptoms and diagnosis of cancer.
Although not statistically significant, the interval between
symptoms and diagnosis was shorter in patients with H. pylori
than in those without it (median difference of 26 days, P > 0.20).
Also, the shortest median interval to diagnosis was in patients with
non-invasive stages and HP present, whereas the longest interval
was for those with invasive stages and without HP (Table 1). The
results support the argument that the cancer is found sooner in
those with rather than without HP.
The paradoxical finding of HP, or its antibodies, more often in
relatively early stages of gastric cancer than in advanced ones has
been previously observed (Caruso and Fucci, 1990). A proposed
explanation has been a change in the conditions favouring HP
persistence as the tumour grows (Forman et al, 1994), but an alter-
native explanation is that the association between HP and gastric
cancer has been distorted by detection bias, specifically in test
ordering. The dyspeptic symptoms caused by the infection lead to
an endoscopy, or an X-ray study, in which a still symptomless
gastric tumour is found. Thus, in patients with gastric neoplasia,
coexistence of HP infection increases the likelihood of going to a
physician and having an endoscopy (or a GI X-ray series). Without
the infection, the tumour may not be detected until it advances to
produce unequivocal symptoms.
The issue is important because several trials are now under way
to test the benefits of mass eradication of HP for ‘preventing’
gastric cancer (Danesh, 1999). The elimination of the infection,
however, may remove the benefit of its sentinel role in early detec-
tion and may worsen an already high ratio of advanced to non-
advanced cases of this common malignancy.
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Table 1 Time to diagnosis in gastric cancer according to stage and
presence of Helicobacter pylori
95% Confidence 
Tumour Helicobacter n Median (days) Interval (days)
stage pylori
Non- Present 13 49 21.5 to 179
Invasive Absent 35 121 55 to 265
Invasive Present 38 176 110.5 to 366.8
Absent 285 185 95 to 324.5